Book Review: 'Slow Dancing With a Stranger'
In gritty and sometimes harrowing detail, activist Meryl Comer describes the reality of caring for a loved one with Alzheimer’s disease.
125 RESULTS
Sort By:
In gritty and sometimes harrowing detail, activist Meryl Comer describes the reality of caring for a loved one with Alzheimer’s disease.
Families considering PGD to avoid passing on disease genes face obstacles such as high cost and invasive procedures.
Several thousand people have used preimplantation genetic diagnosis to avoid passing on pathogenic mutations to their babies, but many families with a history of Alzheimer’s or related diseases remain unaware of this option.
The largest meta-analysis done to date confirms dramatic variability in age at onset of autosomal-dominant Alzheimer's disease overall, but finds mutation type and parental age at onset to be strong predictive modulators.
By paring back calcium signaling, researchers prevented signs of Alzheimer’s in mice carrying a presenilin mutation. Could the strategy work in humans?
The first longitudinal data from DIAN conflict with some cross-sectional findings, revealing a small drop in CSF injury markers after the first appearance of symptoms of disease.
Public funding is becoming so scarce that the DIAN researchers are increasingly asking industry to help...
Families participating in the DIAN made an impassioned case for pressing on with clinical trials at two recent gatherings of the network...
DIAN leaders wrestled with the sensitive issue of genetic confidentiality when reporting data in scientific publications...
When the Dominantly Inherited Alzheimer Network gathered at the its hub at Washington University, St. Louis, Missouri, researchers exchanged new science on ARIA...
A new study suggests that early and late-onset forms of Alzheimer's disease may bear little resemblance at the molecular level...
Researchers with eyes peeled toward prodromal AD probably see the diagram of the field’s five most validated markers in their sleep...
A new group called CAP introduced itself, then three prevention initiatives gave a brief update and stood for extended discussion with the audience...
When the DIAN convened its Pharma Consortium, its scientists intended to brief the Food and Drug Administration on how far DIAN’s work has advanced to date...
The Dominantly Inherited Alzheimer Network Pharma Consortium met in Washington, D.C., to exchange the latest information on DIAN’s preparation for therapeutic trials...